Known targets — ChEMBL curated mechanism
ACHECHRM1CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNG
The experimentally established mechanism targets of Iodide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 known ✓ | P11229 | 1/20 | 0.50 |
| ▸ | PTGS2 | P35354 | 7/20 | 0.59 |
| ▸ | PTGS1 | P23219 | 4/20 | 0.54 |
| ▸ | CXCR1 | P25024 | 3/20 | 0.54 |
| ▸ | CXCR2 | P25025 | 3/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.54 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.54 |
| ▸ | ALB | P02768 | 1/20 | 0.54 |
| ▸ | ESR1 | P03372 | 1/20 | 0.54 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.54 |
| ▸ | RARB | P10826 | 1/20 | 0.54 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.54 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.54 |
| ▸ | HTR2A | P28223 | 1/20 | 0.54 |
| ▸ | NR1I3 | Q14994 | 1/20 | 0.54 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.54 |
| ▸ | CXCL8 | P10145 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10071524 | 0.99 | PTGS2 (0.60) | PTGS2PTGS1CXCR1CXCR2LMNA | |
| SCHEMBL18875740 | 0.83 | PTGS2 (0.53) | PTGS2PTGS1CXCR1CXCR2LMNA | |
| SCHEMBL12884181 | 0.82 | PTGS2 (0.64) | PTGS2PTGS1CXCR1CXCR2LMNA | |
| SCHEMBL12715089 | 0.82 | PTGS2 (0.64) | PTGS2PTGS1CXCR1CXCR2LMNA | |
| SCHEMBL11572717 | 0.82 | PTGS2 (0.64) | PTGS2PTGS1CXCR1CXCR2LMNA | |
| SCHEMBL8024626 | 0.82 | PTGS2 (0.64) | PTGS2PTGS1CXCR1CXCR2LMNA | |
| SCHEMBL7787624 | 0.81 | PTGS2 (0.63) | PTGS2PTGS1CXCR1CXCR2LMNA | |
| SCHEMBL17854658 | 0.81 | PTGS2 (0.63) | PTGS2PTGS1CXCR1CXCR2LMNA | |
| SCHEMBL19376388 | 0.81 | PTGS2 (0.63) | PTGS2PTGS1CXCR1CXCR2LMNA | |
| Bromide SCHEMBL29662199 | 0.80 | PTGS2 (0.50) | PTGS2PTGS1CXCR1CXCR2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120010168-A1 | Unique Dual-Action Therapeutics | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY | 2012-01-12 | — | — | US | claimed |
| WO-2010051044-A1 | UNIQUE DUAL-ACTION THERAPEUTICS | UNIVERSITY OF MEDICINE AND DENTISTRY (US) | 2010-05-06 | — | — | WO | claimed |
| US-10570161-B2 | Unique dual-action therapeutics | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2020-02-25 | — | — | US | disclosed |
| US-20170143836-A1 | UNIQUE DUAL-ACTION THERAPEUTICS | LEHIGH UNIVERSITY | 2017-05-25 | — | — | US | disclosed |
| US-20120010168-A1 | Unique Dual-Action Therapeutics | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY | 2012-01-12 | — | — | US | disclosed |
| WO-2010051044-A1 | UNIQUE DUAL-ACTION THERAPEUTICS | UNIVERSITY OF MEDICINE AND DENTISTRY (US) | 2010-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120010168-A1 | Unique Dual-Action Therapeutics | ACHE, PDE1A, PDE1C | CHRM1 14/4885PTGS2 17/4885PTGS1 28/4885 |
| US-20170143836-A1 | UNIQUE DUAL-ACTION THERAPEUTICS | ACHE, PDE1A, PDE1C | CHRM1 14/4885PTGS2 17/4885PTGS1 28/4885 |
| US-10570161-B2 | Unique dual-action therapeutics | ACHE, PDE1A, PDE1C | CHRM1 13/4885PTGS2 19/4885PTGS1 28/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.